首页 News 正文

JAK1 inhibitor Xibico? New indications for age expansion approved in China

嫦娥的情人矩
1236 0 0

Southern Finance and Economics, March 4th - Today, Pfizer announced that it is a highly selective JAK1 inhibitor and an innovative oral small molecule targeted drug called Xibico; Reg; The new indication for age expansion has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of moderate to severe atopic dermatitis (AD) in adolescents and adults aged 12 and above. (21st Century Business Herald)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

嫦娥的情人矩 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    2